Form 4: Regeneron Director Exercises Options, Sells Shares

Regeneron Pharmaceuticals Director Bonnie L. Bassler exercised stock options and subsequently sold 1,500 shares of common stock on January 7, 2026, under a pre-arranged 10b5-1 plan.

Summary

• Bonnie L. Bassler, a Director at Regeneron Pharmaceuticals, Inc. (REGN), engaged in transactions involving the company's common stock.
• On January 7, 2026, Bassler acquired 1,500 shares of common stock by exercising non-qualified stock options at a price of $374.12 per share.
• Concurrently, Bassler disposed of 1,500 shares of common stock at a volume-weighted average price of $800.00 per share, with prices ranging from $800.00 to $800.01.
• These transactions were executed pursuant to a Rule 10b5-1(c) plan adopted on May 2, 2025.
• Following these transactions, Bassler beneficially owns 1,703 shares of common stock directly and 2,861 non-qualified stock options directly.

Sentiment

Score: 5

Explanation: Neutral. This is a routine insider transaction under a 10b5-1 plan, which is a common practice for executive compensation and personal financial management. It does not inherently signal positive or negative company performance.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 plan, indicating planned activity rather than a reactive sale.
• The sale price of $800.00 per share is significantly higher than the exercise price of $374.12, indicating a profitable transaction for the insider.

Negatives

• A director selling shares, even under a 10b5-1 plan, can sometimes be perceived negatively by some investors, though it is a common practice for compensation and diversification.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This Form 4 filing details a routine insider transaction for a director at a major biotechnology company. Such transactions are common for executive compensation and personal financial planning, especially when executed under a Rule 10b5-1 plan, which allows insiders to sell shares at predetermined times to avoid accusations of trading on material non-public information. It does not provide specific insights into broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: The sale of shares by a director, even under a 10b5-1 plan, slightly increases the float but is generally not significant enough to impact the broader shareholder base or company valuation unless it is a very large, unexpected sale. This appears to be a routine transaction.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction by a director, exercising stock options and selling shares under a pre-arranged 10b5-1 plan. Such transactions are common for executive compensation and personal financial planning and do not typically provide new material information about the company's operational performance or future prospects. Therefore, it does not warrant a change in investment recommendation based solely on this filing. Investors should continue to hold based on broader company fundamentals and market conditions.

Keywords

Regeneron Pharmaceuticals, REGN, Insider Trading, Form 4, Stock Option Exercise, Share Sale, 10b5-1 Plan, Director Transaction, Biotechnology, Pharmaceuticals